A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)

Relapsed or Refractory Diffuse Large B-Cell Lymphoma Clinical Trial

Official title:
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Clinical Trial Details

NCT number	NCT05144841
Study type	Interventional
Source	Merck Sharp & Dohme LLC
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	January 8, 2022
Completion date	June 10, 2025

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT04279938` - A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCL	Phase 1
Active, not recruiting	`NCT04049825` - A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL	Phase 1
Suspended	`NCT04607772` - Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)	Phase 1/Phase 2
Active, not recruiting	`NCT06074107` - Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects	Phase 2